Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Advertisement

Advertisement




Aug
05
Today In Oncology
When Diagnosis Waits: Lung Cancer, PET Access, and Global Oncology
Phase I Trial Evaluates Allogeneic CD70-Targeted CAR T-Cell Therapy in Advanced Renal Cell Carcinoma
Combination Regimen Prolongs PFS in dMMR-MSI-H Metastatic Colorectal Cancer
CKM Syndrome Associated With Increased, Stage-Specific Cancer Risk, Study Finds
Population-Based MGUS Screening Enables Earlier Detection of Multiple Myeloma Without Increasing Psychological Distress
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo